Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jose Willemse"'
Autor:
Claudia Mighiu, Sonia O’Hara, Enrico Ferri Grazzi, Karen F. Murray, Jörn M. Schattenberg, Emily Ventura, Melanie Karakaidos, Alison Taylor, Harpreet Brrang, Anil Dhawan, Jose Willemse, Alan Finnegan
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 17, Iss 1, Pp 1-9 (2022)
Abstract Background Progressive familial intrahepatic cholestasis (PFIC) is a spectrum of rare genetic diseases characterized by inadequate bile secretion that requires substantial ongoing care, though little research is published in this area. We re
Externí odkaz:
https://doaj.org/article/e0b23825ac854b53acaf7e8711c99ff9
Autor:
Louis C. Penning, Marina Berenguer, Anna Czlonkowska, Kay L. Double, Petr Dusek, Carmen Espinós, Svetlana Lutsenko, Valentina Medici, Wiebke Papenthin, Wolfgang Stremmel, Jose Willemse, Ralf Weiskirchen
Publikováno v:
Biomedicines, Vol 11, Iss 2, p 420 (2023)
Wilson disease (WD) is a rare, inherited metabolic disorder manifested with varying clinical presentations including hepatic, neurological, psychiatric, and ophthalmological features, often in combination. Causative mutations in the ATP7B gene result
Externí odkaz:
https://doaj.org/article/acc995f2df7b45f3959c8fccf8a57327
Autor:
Borgsteede, Sander D., Rianne Weersink, Manon van der Wal, Marjan J. Westerman, Jose Willemse, Katja Taxis
Publikováno v:
Borgsteede, S D, Weersink, R, van der Wal, M, Westerman, M, Willemse, J & Taxis, K 2017, ' Informational needs about medication of patients with liver cirrhosis ', International Journal of Clinical Pharmacy, vol. 39, no. 1, pp. 250-250 .
International Journal of Clinical Pharmacy, 39(1), 250-250. Springer Netherlands
International Journal of Clinical Pharmacy, 39(1), 250-250. SPRINGER
Vrije Universiteit Amsterdam
International Journal of Clinical Pharmacy, 39(1), 250-250. Springer Netherlands
International Journal of Clinical Pharmacy, 39(1), 250-250. SPRINGER
Vrije Universiteit Amsterdam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::94d559ad04eedfebdc40ec1874a564d8
https://hdl.handle.net/1871.1/17c2c3e3-b132-40b9-b37d-e618ec63e494
https://hdl.handle.net/1871.1/17c2c3e3-b132-40b9-b37d-e618ec63e494
Autor:
Sven M. Francque, Giulio Marchesini, Achim Kautz, Martine Walmsley, Rebecca Dorner, Jeffrey V. Lazarus, Shira Zelber-Sagi, Kate Hallsworth, Luca Busetto, Gema Frühbeck, Dror Dicker, Euan Woodward, Marko Korenjak, José Willemse, Gerardus H. Koek, Shlomo Vinker, Mehmet Ungan, Juan M. Mendive, Christos Lionis
Publikováno v:
JHEP Reports, Vol 3, Iss 5, Pp 100322- (2021)
Summary: This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and comes with a high disease burden. Yet, there is a lot of
Externí odkaz:
https://doaj.org/article/5859980da3ca44949142e0cb780c5d1c